These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29545966)

  • 1. Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.
    Zhang J; Qian X; Liu F; Guo X; Gu F; Fu L
    Cancer Biol Med; 2018 Feb; 15(1):29-38. PubMed ID: 29545966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation.
    Qian XL; Li YQ; Yu B; Gu F; Liu FF; Li WD; Zhang XM; Fu L
    PLoS One; 2013; 8(3):e60046. PubMed ID: 23533663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependency of Tamoxifen Sensitive and Resistant ER
    Bhasin S; Dusek C; Peacock JW; Cherkasov A; Wang Y; Gleave M; Ong CJ
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
    Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R; Huang M; Lewis-Wambi J
    Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 10. Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in MCF7, T47D and BT483 breast cancer cell lines.
    Baker R; Dell'Acqua G; Richards A; Thornton MJ
    PLoS One; 2024; 19(2):e0297080. PubMed ID: 38408073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
    Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
    PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ELF5 and DOK7 regulation in anti-estrogen treated cells and tumors.
    Fitzgerald LM; Browne EP; Christie KD; Punska EC; Simmons LO; Williams KE; Pentecost BT; M Jawale R; Otis CN; Arcaro KF
    Cancer Cell Int; 2016; 16():8. PubMed ID: 26884724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.
    Daniel AR; Gaviglio AL; Knutson TP; Ostrander JH; D'Assoro AB; Ravindranathan P; Peng Y; Raj GV; Yee D; Lange CA
    Oncogene; 2015 Jan; 34(4):506-15. PubMed ID: 24469035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
    Song C; Kendi AT; Shim JY; Jung D; Kang PS; Lowe VJ; Lee S
    Breast Cancer; 2023 May; 30(3):436-452. PubMed ID: 36859733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer.
    Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G
    Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
    Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
    Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B; García-Roman J; Sommer AK; Wagner E; Roidl A
    Breast; 2019 Feb; 43():31-38. PubMed ID: 30415143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.